Volume 28, Issue 2 (2025)
mjms 2025, 28(2): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khalili A, Karim H, Goudarzvand M, Bayat G. Drug-drug interactions in pharmacotherapy of heart failure: Risk of electrolyte abnormalities. mjms 2025; 28 (2)
URL: http://mjms.modares.ac.ir/article-30-79596-en.html
URL: http://mjms.modares.ac.ir/article-30-79596-en.html
1- Evidence-based Phytotherapy and Complementary Medicine Research Center, Alborz University of Medical Sciences, Karaj, Iran Department of Physiology-Pharmacology-Medical Physics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
2- Cardiovascular research center, Alborz University of Medical Sciences, Karaj, IranDepartment of Cardiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
3- Department of Physiology-Pharmacology-Medical Physics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
4- Evidence-based Phytotherapy and Complementary Medicine Research Center, Alborz University of Medical Sciences, Karaj, Iran Department of Physiology-Pharmacology-Medical Physics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran ,g.bayat@abzums.ac.ir
2- Cardiovascular research center, Alborz University of Medical Sciences, Karaj, IranDepartment of Cardiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
3- Department of Physiology-Pharmacology-Medical Physics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
4- Evidence-based Phytotherapy and Complementary Medicine Research Center, Alborz University of Medical Sciences, Karaj, Iran Department of Physiology-Pharmacology-Medical Physics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran ,
Abstract: (35 Views)
Heart failure (HF) is associated with several systemic complications that require combination therapies. Considering the type and clinical manifestations of HF, several types of medications are used to overcome some harmful activated compensatory mechanisms. Angiotensin receptor–neprilysin inhibitors (ARNIs), angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs) and sodium–glucose cotransporter 2 (SGLT2) inhibitors alongside with other classes like diuretics, vasodilators and/or positive inotropic agents constitute the medication basket for patients with heart failure. Polypharmacy with different classes of drugs increases the risk of drug-drug interactions during treatment. One of the main issues in these interactions is the risk of electrolyte abnormalities, especially regarding the potassium level, which would be so threatening. This mini review focused on specific aspects of drug-drug interactions that might occur during treatment and how they can be life-threatening.
Keywords: Heart failure, ARNIs, SGLT2 inhibitors, ARBs, ACEIs, Drug-interaction, Electrolyte abnormalities
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |